Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity

Kidney International

Volumn 79, Issue 2, 2011, Pages 162-168

  Yvan Charvet, Laurent ^a   Quignard Boulangé, Annie ^b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b INRA Institut National de la Recherche Agronomique   (France)

Author keywords

adipose tissue; angiotensin receptors; angiotensinogen; insulin resistance; obesity

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSINOGEN; CHEMOKINE RECEPTOR CCR2; MESSENGER RNA;

ADIPOCYTE; ADIPOSE TISSUE; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY WEIGHT; CELL DIFFERENTIATION; CELL METABOLISM; DISEASE ASSOCIATION; DOWN REGULATION; ENERGY BALANCE; GENE EXPRESSION; GLUCOSE HOMEOSTASIS; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIPID STORAGE; LIPOGENESIS; LIPOLYSIS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; UPREGULATION;

EID: 78650919357     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.391     Document Type: Short Survey

References (88)

1. Engeli S, Schling P, Gorzelniak K et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol 2003; 35: 807-825.
2. Massiera F, Bloch-Faure M, Ceiler D et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001; 15: 2727-2729.
3. Darimont C, Vassaux G, Ailhaud G et al. Differentiation of preadipose cells: role of prostacyclin upon stimulation of adipose cells by angiotensin-II. Endocrinology 1994; 135: 2030-2036.
4. Crandall DL, Armellino DC, Busler DE et al. Angiotensin II receptors in human preadipocytes: role in cell cycle regulation. Endocrinology 1999; 140: 154-158.
5. Weiland F, Verspohl EJ. Variety of angiotensin receptors in 3T3-L1 preadipose cells and differentiated adipocytes. Horm Metab Res 2008; 40: 760-766.
6. Frederich RC, Kahn BB, Peach MJ et al. Tissue-specific nutritional regulation of angiotensinogen in adipose tissue. Hypertension 1992; 19: 339-344.
7. Hainault I, Nebout G, Turban S et al. Adipose tissue-specific increase in angiotensinogen expression and secretion in the obese (fa/fa) Zucker rat. Am J Physiol Endocrinol Metab 2002; 282: E59-E66.
8. Van Harmelen V, Ariapart P, Hoffstedt J et al. Increased adipose angiotensinogen gene expression in human obesity. Obes Res 2000; 8: 337-341.
9. Massiera F, Seydoux J, Geloen A et al. Angiotensinogen-deficient mice exhibit impairment of diet-induced weight gain with alteration in adipose tissue development and increased locomotor activity. Endocrinology 2001; 142: 5220-5225.
10. Yvan-Charvet L, Even P, Bloch-Faure M et al. Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes 2005; 54: 991-999.
11. Kouyama R, Suganami T, Nishida J et al. Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor. Endocrinology 2005; 146: 3481-3489.
12. Santos SH, Fernandes LR, Mario EG et al. Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism. Diabetes 2008; 57: 340-347.
13. Takahashi N, Li F, Hua K et al. Increased energy expenditure, dietary fat wasting, and resistance to diet-induced obesity in mice lacking renin. Cell Metab 2007; 6: 506-512.
14. Jayasooriya AP, Mathai ML, Walker LL et al. Mice lacking angiotensinconverting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance. Proc Natl Acad Sci USA 2008; 105: 6531-6536.
15. Mathai ML, Naik S, Sinclair AJ et al. Selective reduction in body fat mass and plasma leptin induced by angiotensin-converting enzyme inhibition in rats. Int J Obes 2008; 32: 1576-1584.
16. de Kloet AD, Krause EG, Kim DH et al. The effect of angiotensinconverting enzyme inhibition using captopril on energy balance and glucose homeostasis. Endocrinology 2009; 150: 4114-4123.
17. Lee MH, Song HK, Ko GJ et al. Angiotensin receptor blockers improve insulin resistance in type 2 diabetic rats by modulating adipose tissue. Kidney Int 2008; 74: 890-900.
18. Furuhashi M, Ura N, Higashiura K et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76-81.
19. Clasen R, Schupp M, Foryst-Ludwig A et al. PPARg-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005; 46: 137-143.
20. Janke J, Engeli S, Gorzelniak K et al. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 2002; 51: 1699-1707.
21. Brucher R, Cifuentes M, Acuna MJ et al. Larger anti-adipogenic effect of angiotensin II on omental preadipose cells of obese humans. Obesity 2007; 15: 1643-1646.
22. Tomono Y, Iwai M, Inaba S et al. Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models. Am J Hypertens 2008; 21: 206-212.
23. Dudley DT, Summerfelt RM. Regulated expression of angiotensin II (AT2) binding sites in R3T3 cells. Regul Pept 1993; 44: 199-206.
24. Kambayashi Y, Nagata K, Ichiki T et al. Insulin and insulin-like growth factors induce expression of angiotensin type-2 receptor in vascularsmooth- muscle cells. Eur J Biochem 1996; 239: 558-565.
25. Yvan-Charvet L, Massiera F, Lamande N et al. Deficiency of angiotensin type 2 receptor rescues obesity but not hypertension induced by overexpression of angiotensinogen in adipose tissue. Endocrinology 2009; 150: 1421-1428.
26. Matsushita K, Wu Y, Okamoto Y et al. Local renin angiotensin expression regulates human mesenchymal stem cell differentiation to adipocytes. Hypertension 2006; 48: 1095-1102.
27. Jones BH, Standridge MK, Moustaid N. Angiotensin II increases lipogenesis in 3T3-L1 and human adipose cells. Endocrinology 1997; 138: 1512-1519.
28. Shiuchi T, Iwai M, Li HS et al. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 2004; 43: 1003-1010.
29. Tondu AL, Robichon C, Yvan-Charvet L et al. Insulin and angiotensin II induce the translocation of scavenger receptor class B, type I from intracellular sites to the plasma membrane of adipocytes. J Biol Chem 2005; 280: 33536-33540.
30. Yvan-Charvet L, Bobard A, Bossard P et al. In vivo evidence for a role of adipose tissue SR-BI in the nutritional and hormonal regulation of adiposity and cholesterol homeostasis. Arterioscler Thromb Vasc Biol 2007; 27: 1340-1345.
31. Rao P, Huang ZH, Mazzone T. Angiotensin II regulates adipocyte apolipoprotein E expression. J Clin Endocrinol Metab 2007; 92: 4366-4372.
32. Laffitte BA, Repa JJ, Joseph SB et al. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci USA 2001; 98: 507-512.
33. Boschmann M, Ringel J, Klaus S et al. Metabolic and hemodynamic response of adipose tissue to angiotensin II. Obes Res 2001; 9: 486-491.
34. Goossens GH, Blaak EE, Arner P et al. Angiotensin II: a hormone that affects lipid metabolism in adipose tissue. Int J Obes 2007; 31: 382-384.
35. Goossens GH, Blaak EE, Saris WH et al. Angiotensin II-induced effects on adipose and skeletal muscle tissue blood flow and lipolysis in normal-weight and obese subjects. J Clin Endocrinol Metab 2004; 89: 2690-2696.
36. Yvan-Charvet L, Even P, Lamande N et al. Prevention of adipose tissue depletion during food deprivation in angiotensin type 2 receptordeficient mice. Endocrinology 2006; 147: 5078-5086.
37. Olivares-Reyes JA, Arellano-Plancarte A, Castillo-Hernandez JR. Angiotensin II and the development of insulin resistance: implications for diabetes. Mol Cell Endocrinol 2009; 302: 128-139.
38. Goossens GH, McQuaid SE, Dennis AL et al. Angiotensin II: a major regulator of subcutaneous adipose tissue blood flow in humans. J Physiol 2006; 571: 451-460.
39. Beard KM, Lu H, Ho K et al. Bradykinin augments insulin-stimulated glucose transport in rat adipocytes via endothelial nitric oxide synthasemediated inhibition of Jun NH2-terminal kinase. Diabetes 2008; 55: 2678-2687.
40. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-867.
41. Mazzone T. Adipose tissue and the vessel wall. Curr Drug Targets 2007; 8: 1190-1195.
42. Ferrante Jr AW. Obesity-induced inflammation: a metabolic dialogue in the language of inflammation. J Intern Med 2007; 262: 408-414.
43. Lacasa D, Taleb S, Keophiphath M et al. Macrophage-secreted factors impair human adipogenesis: involvement of proinflammatory state in preadipocytes. Endocrinology 2007; 148: 868-877.
44. Harrison DG, Guzik TJ, Goronzy J et al. Is hypertension an immunologic disease? Curr Cardiol Rep 2008; 10: 464-469.
45. Skurk T, van Harmelen V, Hauner H. Angiotensin II stimulates the release of interleukin-6 and interleukin-8 from cultured human adipocytes by activation of NF-kB. Arterioscler Thromb Vasc Biol 2004; 24: 1199-1203.
46. Tsuchiya K, Yoshimoto T, Hirono Y et al. Angiotensin II induces monocyte chemoattractant protein-1 expression via a nuclear factor-kB-dependent pathway in rat preadipocytes. Am J Physiol Endocrinol Metab 2006; 291: E771-E778.
47. Jurewicz M, McDermott DH, Sechler JM et al. Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation. J Am Soc Nephrol 2007; 18: 1093-1102.
48. Kurata A, Nishizawa H, Kihara S et al. Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 2006; 70: 1717-1724.
49. Hwang D. Modulation of the expression of cyclooxygenase-2 by fatty acids mediated through toll-like receptor 4-derived signaling pathways. FASEB J 2001; 15: 2556-2564. (Pubitemid 33131082)
50. Yvan-Charvet L, Welch C, Pagler TA et al. Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation 2008; 118: 1837-1847.
51. Lu H, Boustany-Kari CM, Daugherty A et al. Angiotensin II increases adipose angiotensinogen expression. Am J Physiol Endocrinol Metab 2007; 292: E1280-E1287.
52. Dusserre E, Moulin P, Vidal H. Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues. Biochim Biophys Acta 2000; 1500: 88-96.
53. Umemura S, Nyui N, Tamura K et al. Plasma angiotensinogen concentrations in obese patients. Am J Hypertens 1997; 10: 629-633.
54. Cooper R, Forrester T, Ogunbiyi O et al. Angiotensinogen levels and obesity in four black populations. J Hypertens 1998; 16: 571-575.
55. Carey RM, Padia SH. Angiotensin AT2 receptors: control of renal sodium excretion and blood pressure. Trends Endocrinol Metab 2008; 19: 84-87.
56. Siragy HM, Xue C, Abadir P et al. Angiotensin subtype-2 receptors inhibit renin biosynthesis and angiotensin II formation. Hypertension 2005; 45: 133-137.
57. Yiannikouris F, Gupte M, Putnam K et al. Adipokines and blood pressure control. Curr Opin Nephrol Hypertens 2010; 19: 195-200.
58. Goossens GH, Jocken JW, Blaak EE et al. Endocrine role of the renin-angiotensin system in human adipose tissue and muscle: effect of beta-adrenergic stimulation. Hypertension 2007; 49: 542-547.
59. Townsend RR, DiPette DJ. Pressor doses of angiotensin II increase insulinmediated glucose uptake in normotensive men. Am J Physiol 1993; 265: E362-E366.
60. Buchanan TA, Thawani H, Kades W et al. Angiotensin II increases glucose utilization during acute hyperinsulinemia via a hemodynamic mechanism. J Clin Invest 1993; 92: 720-726.
61. Juan CC, Chien Y, Wu LY et al. Angiotensin II enhances insulin sensitivity in vitro and in vivo. Endocrinology 2005; 146: 2246-2254.
62. Ogihara T, Asano T, Ando K et al. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 2002; 40: 872-879.
63. Cassis LA, Marshall DE, Fettinger MJ et al. Mechanisms contributing to angiotensin II regulation of body weight. Am J Physiol Endocrinol Met 1998; 274: E867-E876.
64. Henriksen EJ. Improvement of insulin sensitivity by antagonism of the renin-angiotensin system. Am J Physiol Regul Integ Comp Physiol 2007; 293: R974-R980.
65. Lastra G, Habibi J, Whaley-Connell AT et al. Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology 2009; 150: 2561-2568.
66. Petrie JR, Morris AD, Ueda S et al. Trandolapril does not improve insulin sensitivity in patients with hypertension and type 2 diabetes: a doubleblind, placebo-controlled crossover trial. J Clin Endocrinol Metab 2000; 85: 1882-1889.
67. Goossens GH, Blaak EE, Schiffers PM et al. Effect of short-term ACE inhibitor treatment on peripheral insulin sensitivity in obese insulinresistant subjects. Diabetologia 2006; 49: 3009-3016.
68. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus: part 1. A meta-analysis of randomised clinical trials. Diabetes Metabolism 2004; 30: 487-496.
69. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201-207.
70. The NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362: 1477-1490.
71. Dominguez JR, de la CH, Hurtado A et al. Effect of converting enzyme inhibitors in hypertensive patients with non-insulin-dependent diabetes mellitus. Postgrad Med J 1986; 62(Suppl 1): 66-68.
72. Berne C, Pollare T, Lithell H. Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. Diabetes Care 1991; 14(Suppl 4): 39-47.
73. Shimabukuro M, Tanaka H, Shimabukuro T. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens 2007; 25: 841-848.
74. Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol 2009; 6: 399-409.
75. Renehan AG, Tyson M, Egger M et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569-578.
76. Ting SM, Nair H, Ching I et al. Overweight, obesity and chronic kidney disease. Nephron Clin Pract 2009; 112: c121-c127.
77. Yvan-Charvet L, Wang N, Tall AR. Role of HDL, ABCA1 and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol 2010; 30: 139-143.
78. Crowley SD, Vasievich MP, Ruiz P et al. Glomerular type 1 angiotensin receptors augment kidney injury and inflammation in murine autoimmune nephritis. J Clin Invest 2009; 119: 943-953.
79. Rader DJ, Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature 2008; 451: 904-913.
80. Tsubakimoto Y, Yamada H, Yokoi H et al. Bone marrow angiotensin AT1 receptor regulates differentiation of monocyte lineage progenitors from hematopoietic stem cells. Arterioscler Thromb Vasc Biol 2009; 29: 1529-1536.
81. Swirski FK, Nahrendorf M, Etzrodt M et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 2009; 325: 612-616.
82. Fukuda D, Sata M, Ishizaka N et al. Critical role of bone marrow angiotensin II type 1 receptor in the pathogenesis of atherosclerosis in apolipoprotein E deficient mice. Arterioscler Thromb Vasc Biol 2008; 28: 90-96.
83. Ishibashi M, Egashira K, Zhao Q et al. Bone marrow-derived monocyte chemoattractant protein-1 receptor CCR2 is critical in angiotensin II-induced acceleration of atherosclerosis and aneurysm formation in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol 2004; 24: e174-e178.
84. Lu H, Rateri DL, Feldman DL et al. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest 2008; 118: 984-993.
85. Liao TD, Yang XP, Liu YH et al. Role of inflammation in the development of renal damage and dysfunction in angiotensin II-induced hypertension. Hypertension 2008; 52: 256-263.
86. Cassis LA, Rateri DL, Lu H et al. Bone marrow transplantation reveals that recipient AT1a receptors are required to initiate angiotensin II-induced atherosclerosis and aneurysms. Arterioscler Thromb Vasc Biol 2007; 27: 380-386.
87. Kato H, Ishida J, Nagano K et al. Deterioration of atherosclerosis in mice lacking angiotensin II type 1A receptor in bone marrow-derived cells. Lab Invest 2008; 88: 731-739.
88. Iwai M, Chen R, Li Z et al. Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice. Circulation 2005; 112: 1636-1643.